Zusammenfassung
Das Kaposi-Sarkom (KS) ist eine multifokale, von mesenchymalen Zellen ausgehende Neoplasie unklarer Genese an Haut und inneren Organen, deren Erstbeschreibung „Sarcoma idiopathicum multiplex haemorrhagicum“ durch Moritz Kaposi 1872 erfolgte [78]. Es wird auch als europäisches oder klassisches KS bezeichnet. Daneben finden sich das afrikanische KS und das KS bei iatrogener Immunsuppression. Vielfältiges wissenschaftliches Interesse erweckte dieser Tumor, nachdem Friedman-Kien et al. 1981 [49] über das gehäufte Auftreten von KS bei jungen homosexuellen Männern in New York berichteten, die gleichzeitig an einer erworbenen Immunschwäche erkrankt waren. Dieser Zusammenhang war so charakteristisch, daß ein Zusammenhang schon vor der Entdeckung des „human immunodeficiency virus“ (HIV) offensichtlich schien und das KS, verbunden mit einer nicht erklärbaren Immunschwäche, als AIDS-definierend eingestuft und diese Variante des KS als epidemisches KS bezeichnet wurde [50,92,104].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Ackerman AB, Gottlieb GJ (1988) Atlas of the gross and microscopic features. In: Gottlieb G, Ackerman AB (eds) Kaposi′s sarcoma: a text and atlas. Febiger, Philadelphia, pp 29 – 63
Baggish MS, Poiesz BJ, Joert D (1991) Presence of virus human immunodeficiency DNA in laser smoke. Laser Surg Med 11: 197 – 203
Bailey J, Pluda JM, Foli A et al. (1995) Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with interferon alfa-2a, in patients with epidemic Kaposi′s sarcoma. J Clin Oncol 13: 1966 – 1974
Beier C, Schöfer H, Kaufmann R (1996) Topical photodynamic therapy (TPDT) of AIDS-associated kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Beier V, Peterman TA, Berkelman RL, Jaffe HW (1990) Kaposi′s sarcoma amongpersons with AIDS: a sexually transmitted infection? Lancet 335: 123 – 128
Beral V, Bull D, Jaffe H, Evans B, Gill N, Tillett H, Swerdlow AJ (1991) Is risk of Kaposi′s sarcoma in AIDS patients in Britain increased if sexual partners came from United States of America? BMJ 302: 624 – 625
Beral V, Bull D, Darby S, Weller I, Carne C, Beecham M, Jaffe H (1992) Risk of Kaposi′s sarcoma and sexual practices associated with faecal contact in homosexual or bisexual men with AIDS. Lancet 339: 632 – 635
Berson AM, Quivey, JM, Harris JW (1990) Radiationtherapiy for AIDS-related Kaposi′s sarcoma. Int J Radiat Oncol Biol Phys 19: 569 – 575
Bertelli D, Barni C, Casari S, Paraninfo G, Cadeo GP (1996) Adriamycin, bleomycin and vinblastine (ABV) chemotherapy in the treatment of AIDS-related kaposi′s sarcoma (KS). XI. Int Conf AIDS, Vancouver
Biberfeld P, Ekman M, Kaaya EE, Jagdahl L, Linde A, Biberfeld G (1996) HHV8 and other herpes virus in AIDS related and endemic kaposi′s sarcoma (KS) and malignant lymphoma. XI. Int Conf AIDS, Vancouver
Blazques MV, Madueno JA, Jurado R, Fernandez-Arcas N, Munoz E (1995) Human herpesvirus-6 and the course of human immunodeficiency virus infection. J Acquir Immune Defic Syndr Hum Retrovirol 9: 389 – 394
Bogner JR, Kronawitter U, Rolinski B, Truebenbach K, Goebel FD (1993) Liposomal Doxorubicin in the treatment of advanced AIDS-related Kaposi′s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 7: 463 – 468
Bonhomme L, Fredj G, Averons S (1991) Topical treatment of epidermic Kaposi′s sarcoma with alltrans-retinoic acid. Ann Oncol 2: 234 – 235
Boudreaux AA, Smith LL,Cosby CD (1993) Intralesional vinblastin for cutaneous Kaposi′s sarcoma associated with acquired immunodeficiency Syndrome. J Am Acad Dermatol 28: 61 – 65
Bourinbaiar AS, Lee-Huang S (1995) Anti-HIV effect of beta subunit of human chorionic gonadotropin (beta hCG) in vitro. Immunol Lett 44: 13 – 18
Brockmeyer NH (1994) Interferontherapie beim Kaposi-Sarkom. In: Gross G, Bröcker EB (Hrsg) Interferon-Therapie in der Dermatologie, Aktuelle Dermatologie, Bd 11. Zuckschwerdt, München Bern Wien New York, S 71 – 91
Brockmeyer NH, Mertins L, Goos M (1990) Progression of Kaposi′s sarcoma under a combined interferon beta and interferon gamma therapy in AIDS patients. Klin Wochenschr 68: 1229
Brockmeyer NH, Hengge UR, Jura S, Tillmann I, Goos M (1993) Fumagillol and Isotretinoin inhibit in-vitro Kaposi′s sarcoma cell growth. J Invest Dermatol 100: 558
Brockmeyer NH, Mertins L, Hengge UR, Tillmann I, Stürzl M, Goos M (1993) Fumagillol as an inhibitor of in vitro Kaposi′s sarcoma cell growth. Arch Dermatol Res 285: 69
Brockmeyer NH, Mertins L, Hengge U, Stürzl M, Anders S, Goos M (1993) Wirkung von Interferon auf Kaposi-Sarkom-Zellinien. Zbl Haut 162: 170
Brockmeyer NH, Mertins L, Goos M (1994) Therapie des HlV-assoziierten Kaposi-Sarkoms. AIFO 9: 483 – 489
Brockmeyer NH, Reimann G, Mertins L, Goos M (1995) Kaposi-Sarkom-Therapie. In: Tilgen W, Petzold D (Hrsg) Operative und konservative Dermatoonkologie, Bd 10. Springer, Berlin Heidelberg New York Tokyo, S 282 – 288
Brodt HR, Kamps BS, Gute P, Lutz T, Mitrou P, Helm EB (1996) Accelerated course of human immunodeficiency virus infection after kaposi′s sarcoma. A matched control study. XI. Int Conf AIDS, Vancouver
Brooks JJ (1986) Kaposi′s sarcoma: a reversible hyperplasia. Lancet 2: 1309 – 1310
Buonaguro L, Buonaguro FM, Tornesello ML, Beth-Giraldo E, Del Gaudio E, Ensoli B, Giraldi G (1994) Role of HIV-1 Tat in the Pathogenesis of AIDS-Associated Kaposi′s sarcoma. Antibiot Chemother 46: 62 – 72
Cazorla C, Dabis F, Dupon M, Ragnaud JM, Geniaux M, Pellegrin JL, Journot V, Salmi LR (1996) Behavioural risk factors of Kaposi′s sarcoma: A case control study. XI. Int Conf AIDS, Vancouver
Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM (1995) Kaposi′s sarcoma-associated Herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 332: 1186 – 1191
Chang Y, Cesarman E, Pessin S, Lee F, Culpepper J, Knowles DM, Moore PS (1994) Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi′s sarcoma. Science 266: 1865 – 1869
Contu L, Cerimele D, Pintus A, Cottoni F, La Nasa G (1984) HLA and Kaposi′s sarcoma in Sardinia. Tissue Antigens 23: 240 – 245
Cooper JS (1990) Optimal treatment of epidemic Kaposi′s sarcoma. Int J Radiat Oncol Biol Phys 19: 807 – 808
Corbeil J, Rapaport E, Richman DD, Looney DJ (1994) Antiproliferative effect of retinoid Compounds on Kaposi′s sarcoma cells. J Clin Invest 93: 1981 – 1986
Costa da Cunha CS, Lebbe C, Rybojad M, Agbalika F, Ferchal F, Vignon-Pennamen MD, Calvo F, Morel P (1996) Long-term follow-up of non-HIV Kaposi′s sarcoma treated with low-dose recombinant interferon alfa-2b. Arch Dermatol 132: 285 – 290
Dameron KM, Volpert OV, Tainsky MA et al. (1994) Control of anglogenesis in fibroblasts by P53 regulation of thrombospondin-i. Science 265: 1582
Delli Bovi P, Curatola AM, Kern FG, Greco A, Ittmann M, Basilico C (1987) An oncogene isolated by transfection of Kaposi′s sarcoma DNA encodes a growth factor that is a member of the FGF family. Cell 50: 729 – 737
Delli Bovi P, Donti E, Knowles DM, Friedman-Kien A, Luciw PA, Dina D, Dalla-Favera R, Basilico C (1986) Presence of chromosomal abnormalities and lack of AIDS retrovirus DNA sequences in AIDS-associated Kaposi′s sarcoma. Cancer Res 46: 6333 – 6338
Dezube BJ, Fridovich-Keil JL, Bouvard J, Lange RF, Pardee AB (1990) Pentoxifylline and well-being in patients with cancer. Lancet 335: 662
Duvic M, Friedman-Kien AE, Galpin J et al. (1996) Phase I-II clinical trial supports safety and efficacy of ALRT 1057 topical retinoid gel for kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Engst R, Sigl I (1988) Kaposi-Sarkom: Dermatologische Manifestation. AIFO 1: 29 – 32
Ensoli B, Nakamura S, Salahuddin SZ et al. (1989) AIDS-Kaposi′s sarcoma-derived cells express cytokines with autocrine and paracrine growth effects. Science 243: 223 – 226
Ensoli B, Barillari G, Gallo RC (1992) Cytokines and growth factors in the pathogenesis of AIDS-associated Kaposi′s sarcoma. Immunol Rev 127: 147 – 155
Ensoli B, Gendelman R, Markham P et al. (1994) Synergy between basic fibroblast growth factor and HIV-1 Tat protein in induction of Kaposi′s sarcoma. Nature 371: 674 – 680
Epstein JB, Lozada-Nur F, McLeod WA (1989) Oral Kaposi′s sarcoma in acquired immunodeficiency Syndrome: review of management and report of the efficacy of intralesional vinblastine. Cancer 64: 2424 – 2430
Esser S, Bleil M, Reimann G, Mertins L, Brockmeyer NH (1996) Long term treatment with liposomal doxorubicin in patients with AIDS-related kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Fazely F, Dezube BJ, Alien-Ryan J, Pardee AB, Ruprecht RM (1991) Pentoxifylline (Trental) decreases the replication of the human immunodeficiency virus type 1 in human peripheral blood mononuclear cells and in cultured T-cells. Blood 77: 1653 – 1656
Fischl MA, Krown SE, Boyle KP (1993) Weekly doxorubicin in the treatment of patients with AIDS- related Kaposi′s sarcoma. J Acquir Immune Defic Syndr 6: 259 – 264
Fischl MA, Finkelstein DM, He W, Powderly WG, Triozzi PL, Steigbigel RT (1996) A phase II study of recombinant human interferon-alpha 2a and zidovudine in patients with AIDS-related Kaposi′s sarcoma. AIDS Clinical Trials Group. J Acquir Immune Defic Syn Hum Retrovirol 11: 379 – 384
Folks TM, Clouse KA, Justement J, Rabson A, Duh E, Kehrl JH, Fauci AS (1989) Tumor necrosis fac¬tor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc Natl Acad Sei USA 86: 2365 – 2368
Francis ND, Parkin JM, Weber J, Boylston AW (1986) Kaposi′s Sarcoma in acquired immune deficiency Syndrome (AIDS). J Clin Pathol 39: 469 – 474
Friedman-Kien AE, Laubenstein L, Marmor M (1981) Kaposi′s sarcoma and Pneumocystis pneumonia among homosexual men — New York City and California. MMWR 30 /25: 305 – 308
Gallo RC, Salahuddin SZ, Popovic M et al. (1984) Frequent detection and isolation of cytopathic retrovirus (HTLV-III) from patients with AIDS and at risk for AIDS. Science 224: 500 – 503
Gange RW, Wilson-Jones E (1978) Kaposi′s sarcoma and immunosuppressive therapy: an appraisal. Clin Exp Dermatol 3: 135 – 146
Gill PS, Bernstein-Singer M, Espina BM et al. (1992) Adriamycin, bleomycin and vincristine chemotherapy with recombinant granulocyte-macrophage colony-stimulating factor in the treatment of AIDS-related Kaposi′s sarcoma. AIDS 6: 1477 – 1481
Gill PS, Miles SA, Mitsuyasu RT et al. (1994) Phase I AIDS Clinical Trials Group (075) study of adriamycin, bleomycin and vincristine chemotherapy with zidovudine in the treatment of AIDS-related Kaposi′s sarcoma. AIDS 8: 1695 – 1699
Gill PS, Wernz J, Scadden DT et al. (1996) Randomized Phase III Trial of Liposomal Daunorubicin Versus Doxorubicin, Bleomycin, and Vincristine in AIDS-Related Kaposi′s Sarcoma. J Clin Oncol 8: 2353 – 2364
Giraldo G,Beth E (1986) The involvement of cytomegalovirus in AIDS and Kaposi′s sarcoma. Prog Allergy 37: 319 – 331
Gottlieb GJ, Ackerman AB (1982) Kaposi′s sarcoma: an extensively disseminated form in young homosexual men. Hum Pathol 13: 882 – 892
Grekin R, Razum N, Trommer R, Doiron D, Snyder A (1996) Tin Ethyl etiopurpurin (snet 2) photodynamic therapy (PDT): Results of a phase I/II clinical study conducted at UCSF for the treatment of AIDS-associated cutaneous kaposi′s sarcomas. XI. Int Conf AIDS, Vancouver
Gross G, Pfister H, Wagner B, Brockmeyer NH (1994) Prevalence of antibodies to HPV16-e7-protein does not differ between AIDS-patients with and without Kaposi′s sarcoma. Genitourin Med 70: 70 – 71
Gruenaug M, Bogner JR, Loch O, Goebel F-D (1996) Liposomal doxorubicin in pulmonary kaposi′s sarcoma: Improved survival as compared to patients without liposomal doxorubicin. XI. Int Conf AIDS, Vancouver
Harris PJ (1995) Treatment of Kaposi′s sarcoma and other manifestations of AIDS with human chorionic gonadotropin. Lancet 346: 118 – 119
Harwood AR (1981) Kaposi′s sarcoma: an update on the results of extended field radiotherapy. Arch Dermatol 117: 775 – 777
Harwood AR, Osoba D, Hofstader SL et al. (1979) Kaposi′s sarcoma in recipients of renal transplants. Am J Med 67: 759 – 765
Haverkos HW (1987) Factors associated with the pathogenesis of AIDS. J Infect Dis 156: 251 – 257
Hengge UR, Brockmeyer NH, Mertins L, Wiggen-Klimek A, Anders S, Baumann M, Goos M (1992) In vivo and in vitro production of autocrine growth factors by Kaposi′s sarcoma cells. XX. Jahrestagung ADF, Mainz, 13.-15.11.1992
Hengge UR, Brockmeyer NH, Rasshofer R, Goos M (1993) Fatal hepatic failure with liposomal doxorubicin. Lancet 341: 383 – 384
Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M (1993) Liposomal doxorubicin in AIDS-related Kaposi′s sarcoma. Lancet 342: 497
Henriksson M, Lüscher B (1996) Myc proteins: essential regulators of cell growth. Cancer Res 68: 110 – 169
Hermans P, Gori A, Lemone M, Franchioly P, Clumeck N (1994) Possible role of granulocyte-macrophage colony stimulating factor (GM-CSF) on the rapid progression of AIDS-related Kaposi′s sarcoma lesions in vivo. Brit J Haematol 87: 413 – 414
Hündgen M, Eick H (1990) Pharmakologie von Interferonen (IFN-α, IFN-β, IFN-γ). In: Orfanos, Garbe (Hrsg) Das maligne Melanom der Haut. Zuckschwerdt, München, S 243 – 247
Husain SR, Obiri N, Gill P, Pastan I, Debinski W, Puri RK (1996) Interleukin-13 receptor: A new target for a Pseudomonas exotoxin based chimeric protein on AIDS associated kaposi′s sarcoma cells. XI. Int Conf AIDS, Vancouver
Ihle JN (1996) Signaling by the Cytokine Receptor Superfamily in Normal and Transformed Hematopoietic Cells. Cancer Research 68: 23 – 51
Ingber D, Fujita T, Kishimoto S, Sudo K, Kanamaru T, Brem H, Folkman J (1990) Synthetic analogues of fumagillin that inhibit angiogenesis and suppress tumor growth. Nature 348: 555 – 557
Jauregui Rueda H, Rosetti S, D′Alessandro L, Lewi D, Monticolli A (1996) Detection of herpesvirus-like DNA sequence (KSHV) in HIV positive patients with and without Kaposi′s sarcoma (KS). XI. Int Conf AIDS, Vancouver
Jin Y-T, Tsai S-T, Yan J-J, Hslao J-H, Lee Y-Y, Su I-J (1996) Detection of Kaposi′s Sarcoma-associated Herpesvirus-like DNA Sequence inVascular lesions. A Reliable Diagnostic Marker for Kaposi′s Sarcoma. Am J Clin Pathol 105: 360 – 363
Jones JL, Hanson DL, Chu SY, Ward JW, Jaffe HW (1995) AIDS-associated Kaposi′s sarcoma. Science 267: 1078 – 1080
Kahn J, Kaplan L, Volberding P (1989) Intralesional tumor necrosis factor a for AIDS-associated Kaposi′s sarcoma. J Acquir Immune Defic Syndr 2: 217 – 223
Kahn J, Ruiz R, Kerschmann R (1993) A phase-II-study of recombinant platelet factor 4 (rPF4) in patients with AIDS-related Kaposi′s sarcoma (KS). Proc Am Soc Clin Oncol 12,50 Abstract 4 A
Kaposi M (1872) Idiopathisches multiples Pigmentsarkom der Haut. Arch Derm Syph 4: 265 – 273
Knowles DM (1996) Etiology and Pathogenesis of AIDS-Related Non-Hodgki′s Lymphoma. In: Krown SE, Roenn JV von (eds) Hematology/Oncology clinics of North America. Saunders, Philadelphia London Sydney, 10: 1081
Knowles DM, Chadburn A (1992) Lymphadenopathy and the lymphoid neoplasms associated with the aquired immune deficiency Syndrom (AIDS). In Knoweles DM (ed): Neoplastic Hematopathology, Williams & Wilkins, Baltimore
Krigel RL, Odajnyk CM, Laubenstein LJ et al. (1985) Therapeutic trial of interferon γ in patients with epidemic Kaposi′s sarcoma. J Biol Response Mod 4: 358 – 364
Krown SE (1991) Interferone and other biologic agents for the treatment of Kaposi′s sarcoma. Hematol Oncol Clin North Am 5: 311 – 322
Krown SE (1991) Interferone and other biologic agents for the treatment of Kaposi′s sarcoma. Hematol Oncol Clin North Am 5: 311 – 322
Krown SE, Metroka C, Wernz JC (1989) Kaposi′s sarcoma in the acquired immune deficiency Syndrome: a proposal for uniform evaluation, response, and Staging criteria. AIDS clinical trials group oncology committee. J Clin Oncol 7: 1201 – 1207
Krown SE, Gold JW, Niedzwiecki D, Bundow D, Flomenberg N, Gansbacher B, Brew BJ (1990) Interferon-alpha with zidovudine: safety, tolerance, and clinical and virologic effects in patients with Kaposi sarcoma associated with the acquired immunodeficiency Syndrome (AIDS). Ann Intern Med 112: 812 – 821
Krown SE, Niedzwiecki D, Bhalla RB, Flomenberg N, Bundow D, Chapman D (1991) Relationship and prognostic value of endogenous interferon-alpha, beta 2-microglobulin, and neopterin serum levels in patients with Kaposi sarcoma and AIDS. J Acquir Immune Defic Syndr Hum Retrovirol 14: 871 – 880
Kusaka M, Sudo K, Fujita T, Marui S, Itoh F, Ingber D, Folkman J (1991) Potent anti-angiogenic action of AGM-1470: comparison to the fumagillin parent. Biochem Biophys Res Comm 174: 1070 – 1076
Lampinen TM, Collier AC, Holmes KK (1996) Meta-analysis of acyclovir for kaposi′s sarcoma prophylaxis. XI. Int Conf AIDS, Vancouver
Lane HC, Depper JM, Greene WC, Whalen G, Waldmann TA, Fauci AS (1985) Qualitative analysis of immune function in patients with the acquired immunodeficiency Syndrome. N Engl J Med 313: 79 - 84
Lane HC, Falloon J, Walker RE (1989) Zidovudine in patients with human immunodeficiency virus (HIV) infection and Kaposi′s sarcoma. Ann Intern Med 111: 41 – 50
Lassoued K, Clauvel JP, Katiama C (1990) Treatment of the acquired immune deficiency syndrome-related Kaposi′s sarcoma with bleomycin in as a single agent. Cancer 66: 1869 – 1872
Lemlich G, Schwam L, Lebwohl M (1987) Kaposi′s sarcoma and acquired immunodeficiency Syndrome. J Am Acad Dermatol 16: 319 – 325
Li J-J, Friedman-Kien AE, Hueng YQ, Zhang WG, Feiner D (1996) Detection of HHV-8 in subsets of blood cells from patients with AIDS-related kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Lo SC, Shih JW, Newton PB et al. (1989) Virus-like infectious agent (VLIA) is a novel pathogenic mycoplasma: Mycoplasma incognitus. Am J Trop Med Hyg 41: 486 – 600
Lunardi-Iskandar Y, Bryant-JL, Zeman RA et al. (1995) Tumorigenesis and metastasis of neoplastic Kaposi′s sarcoma cell line in immunodeficient mice blocked by a human pregnancy hormone. Nature 375: 64 – 68
Mauss S, Jablonowski H (1995) Efficacy, safety, and tolerance of low-dose, long-term interferon-alpha 2b and zidovudine in earlystage AIDS-associated Kaposi′s sarcoma. J Acquir Immune Defic Syndr Hum Retrovirol 10: 157 – 162
McNamee D (1995) Beta-hCG inhibits Kaposi′s sarcoma (news). Lancet 345: 1169
Miles SA, Wang HJ, Cortes E et al. (1990) Beta-Interferon therapy in patients with poor-prognosis Kaposi′s sarcoma related to the acquired immunodeficiency Syndrome (AIDS). Ann Intern Med 112: 582 – 589
Miles SA, Martinez-Maza O, Rezai A et al. (1992) Oncostatin M as a potent mitogen for AIDS-Kaposi′s sarcoma-derived cells. Science 247: 77
Mitsuyasu RT, Groopman JE (1984) Biology and therapy of Kaposi′s sarcoma. Semin Oncol 11: 53
Mitsuyasu, RT (1987) Clinical variants and Staging of Kaposi′s sarcoma. Semin Oncol 14: 13
Mitsuyasu RT, Taylor JMG, Glaspy J, Fahey JL (1986) Heterogeneity of epidemic Kaposi′s sarcoma. Implications for therapy. Cancer 57: 1657 – 1661
Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R (1996) Antiherpes virus treatment and risk of Kaposi′s sarcoma in HIV infection. XI. Int Conf AIDS, Vancouver
Montagnier L, Grust J, Chamaret S et al. (1984) Adaption of lymphadenopathy associated virus (LAV) to replication in EBV-transformed B lymphoblastoid cell lines. Science 225: 63 – 66
Moore PS, Chang Y (1995) Detection of Herpesvirus-like DNA sequences in Kaposi′s sarcoma in patients with and without HIV infection. N Engl J Med 332: 1181 – 1185
Morfeldt L, Torssander J (1994) Long-term remission of Kaposi′s sarcoma following foscarnet treat¬ment in HlV-infected patient. Scand J Infect Dis 26: 749 – 752
Morris CB, Gendelman R, Marrogi AJ, Lu M, Lockyer JM, Alperin-Lea W, Ensoli B (1996) Immunihistochemical detection of Bcl-2 in AIDS-associated and classical Kaposi′s sarcoma. Am J Pathol 148: 1055 – 1063
Moskowitz LB, Hensley GT, Gouid EW, Weiss SD (1985) Frequency and anatomic distribution of lymphadenopathic Kaposi′s sarcoma in the acquired immunodeficiency Syndrome: an autopsy series. Hum Pathol 16: 447 – 456
Müsch E (1987) Natürliches menschliches Fibroblasten-Interferon (Hn IFN-b) als additive lokoregionale und systemische Tumortherapie. Acta Immunol 5: 19 – 27
Muzyka BC, Glick M (1993) Sclerotherapy for the treatment of nodular intraoral Kaposi′s sarcoma in patients with AIDS. N Engl J Med 328: 210 – 211
Myskowski PL (1992) Intralesional interferon a-2b produces responses in Kaposi′s sarcoma. Dermatology 3: 11
Nadimi H, Saatee S, Armin A, Toto PD (1988) Expression of endothelial cell markers PAL-E and EN-4 and Ia-antigens in Kaposi′s sarcoma. J Oral Pathol Med 17: 416 – 420
Nakamura S, Sakurada S, Salahuddin SZ (1992) Inhibition of development of Kaposi′s sarcomarelated lesions by a bacterial wall complex. Science 255: 1473 – 1440
Nickoloff BJ, Griffith CE (1989) Factor XIIIa-expressing dermal dendrocytes in AIDS-associated cutaneous Kaposi′s sarcomas. Science 243: 1736 – 1737
Nicolaides A, Huang YQ, Li JJ, Zhang WG, Friedmann-Kien AE (1994) Gene amplification and mul-tiple mutations of the K-ras oncogene in Kaposi′s sarcoma. Anticancer Res 14: 921 – 926
Niedt GW, Myskowski PL, Urmacher C, Niedzwiecki D, Chapman D, Safai B (1990) Histology of early lesions of AIDS-associated Kaposi′s sarcoma. Mod Pathol 3: 64 – 70
Ockenfels HM, Brockmeyer NH, Hengge U, Goos M (1996) Cutaneous angiosarcoma: a novel therapy with liposomal doxorubicin? J Eur Acad Dermatol Venereol 6: 71 – 75
Orfanos CEW, Bratzke B, Lehmann FM (1988) Das HIV-1-assoziierte mukokutane Kaposi-Sarkom. AIFO 3: 561 – 569
Philip R, Debs R (1991) Cytokine-activated human monocytes show differential cytotoxity toward fresh and cultured Kaposi′s sarcoma cells. J Acquir Immune Defic Syndr 4: 1254 – 1257
Penn I (1979) Kaposi′s sarcoma in organ transplant recipients: Report of 20 cases. Transplantation 27: 8 – 11
Picard o, Hermans P, Clumeck N, Gill P, Lunardi-Iskandar Y, Gallo R (1996) Preliminary results with human chorionic gonadotropin in AIDS-related kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Podzamczer D, Baleo F, Clotet B, Carcia P, Casanova A, Paqerols X, Gudiol F (1993) Low-dose interferon alpha combined with zidovadine in patients with AIDS-associated Kaposi′s sarcoma. J Intern Med 233: 247 – 253
Podzamczer D, Gonzalez-Lahoz J, Inchaustegui L et al. (1996) Alpha interferon (IFN) plus zido-vudine in kaposi sarcoma: A randomized trial comparing IFN 3 MU VS. 10 MU daily. XI. Int Conf AIDS, Vancouver
Poizot-Martin I, Giovannini M, Rosello R, Viallat JR, Dalmas AM, Sauniere F, Gastaut JA (1996) TLC D-99 in HIV associated kaposi′s sarcoma (KS). XI. Int Conf AIDS, Vancouver
Poretsky L, Can S, Zumoff B (1995) Testicular dysfunction in human immunodeficiency virusinfected men. Metabolism 44: 946 – 953
Rahman A, Carmichael D, Harris M, Roh JK (1986) Comparative pharmacokinetics of free doxorubicin and doxorubicin entrapped in cardiolipin liposomes. Cancer Res 46: 2295 – 2299
Rahman A, Treat J, Roth JK et al. (1990) A phase I clinical trial and pharmacokinetic evaluation of liposome-encapsulated doxorubicin. J Clin Oncol 8: 1093 – 1100
Rasokat H, Haussermann L, Minnemann M (1989) Response of AIDS-related Kaposi′s sarcoma to treatment with recombinant interferon alpha depends on the stage of underlying immunodeficiency. J Invest Dermatol 89: 444 – 445
Real FX, Krown SE (1985) Spontaneous regression of Kaposi′s sarcoma in patients with AIDS (Letter). N Engl J Med 313: 1659
Real FX, Oettgen HF, Krown SE (1986) Kaposi′s sarcoma and the acquired immunodeficiency Syndrome: treatment with high and low doses of recombinant leukocyte A interferon. J Clin Oncol 4: 544 – 551
Routy J-P, MacLeod J, Urbanek A (1996) Bleomycin + Vincristine/VP16 with or without G-CSF in AIDS patients with kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Safai B (1984) Kaposi′s sarcoma: a review of the classical and epidemic forms. Ann NY Acad Sei 437: 373 – 382
Saiag P, Pavlovic M, Chastang C et al. (1996) Treatment of AIDS-related Kaposi′s sarcoma (AIDS-KS) with alltrans-retinoic acid (ATRA). Results of a phase II trial. XI. Int Conf AIDS, Vancouver
Saillour M, Risbourg M, de Truchis P, Valance A, Sarrazin E, Perronne C (1996) Effects of anti-CMV agents on kaposi sarcoma (KS) in AIDS patients. XI. Int Conf AIDS, Vancouver
Saint-Marc T, Jeanblanc F, Makhloufi D, Touraine JL (1996) Phase II clinical trial of liposomal daunorubicin in the treatment of pulmonary kaposi′s sarcoma. XI. Int Conf AIDS, Vancouver
Saville MW, Lietzau J, Pluda JM et al. (1995) Treatment of HIV-associated Kaposi′s sarcoma with paclitaxel. Lancet 346: 26 – 28
Schirren CG, Roth WK, Hein R, Werner S, Krieg T, Braun-Falco O (1990) Invasive migration of epidermic Kaposi′s sarcoma cells in vitro. Br J Dermatol 123: 313 – 318
Schöfer H, Ochsendorf FR, Hochscheid I, Milbradt R (1991) Facial Kaposi′s sarcoma. Palliative treatment with cryotherapy, intralesional chemotherapy, low-dose roentgen therapy and Camouflage. Hautarzt42: 493 – 498
Schwartsmann G, Sander E, Prolia G (1993) Phase II trial of pentosan polysulfate (PPS) in patients (pts) with AIDS-related Kaposi′s sarcoma (KS). Proc Am Soc Clin Oncol 12: 54, Abstr 18 A
Schwartz RA (1996) Kaposi′s sarcoma: advances and perspectives. J Am Acad Dermatol 34: 804 – 814
Sidky YA, Borden EC (1987) Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res 47: 5155 – 5161
Sirianni MC, Vincenzi L, Topino S, Uccini S, Angeloni A, Aiuti F (1996) Characterization of circulating kaposi′s sarcoma cells. XI. Int Conf AIDS, Vancouver
Smith KJ, Konzelmann JL, Lombardo FA (1992) Iontophoresis of vinblastine into normal skin and for treatment of Kaposi′s sarcoma in human immunodeficiency virus-positive patients. Arch Dermatol 128: 1365 – 1370
Snover DC, Rosai J (1985) Vascular sarcomas of the skin. Clin Biochem Anal 20: 181 – 209
Soderberg LS, Barnett JB (1995) Inhalation expusore to isobutyl nitrite inhibits macrophage tumoricidal activity, and modulates inducible nitric oxide. J Leukoc Biol 57: 135 – 140
Sprinz E, Kalakun L, Proila G et al. (1994) A phase II study of the basic fibroblast growth factor (b-FGF) inhibiting agent pentosan polysulfate (PPS) in patients (pts) with AIDS-related Kaposi′s sarcoma (AIDS-KS). Ann Oncol 5: 3
Starr JC, Kilmer SL, Wheeland RG (1992) Analysis of the carbon dioxide laser plume for simian immunodeficiency virus. J Dermatol Surg Oncol 18: 297 – 300
Stavermann T, Hübner P, Rueß A (1992) Recombinant interferon-beta in the therapy of advanced AIDS-related Kaposi′s sarcoma. VII. Int Conf on AIDS/III World Congr Amsterdam, The Netherlands, 19–24 July
Stewart S, Jablonowski H, Goebel FD, L′Age M, Spittle M, Luthy R (1996) Randomized comparative trial of doxil(r) VS. Bleomycin and vincristin in the treatment of AIDS-related KS. XI. Int Conf AIDS, Vancouver
Stürzl M, Roth WK, Brockmeyer NH, Zietz C, Speiser B, Hofschneider PH (1992) Platelet-derived growth factor (PDGF) and PDGF-receptor. Expression in AIDS-related Kaposi′s sarcoma in vivo suggests paracrine and autocrine mechanismus of tumor maintainance. Proc Natl Acad Sei USA 89: 7046 – 7050
Stürzl M, Brandstetter H, Zietz C et al. (1995) Identification of interleukin-1 and platelet-derived growth factor-B as major mitogens for the spindle cells of Kaposi′s sarcoma: a combined in vitro and in vivo analysis. Oncogene 10: 2007 – 2016
Stribling J, Weitzner S, Smith GV (1978) Kaposi′s sarcoma in renal allograft reeipients. Cancer 42: 442 – 446
Tappero JW, Berger TG, Kaplan LD (1991) Cryotherapy for cutaneous Kaposi′s sarcoma (KS) associated with acquired immune deficiency Syndrome (AIDS): a phase II trial. J Acquir Immune Defic Syndr Hum Retrovirol 4: 839 – 846
Tappero JW, Grekin RC, Zanelli GA (1992) Pulsed-dye laser therapy for cutaneous Kaposi′s sarcoma associated with acquired immunodeficiency Syndrome. J Am Acad Dermatol 27: 526 – 530
Taylor JF, Lange U, Wolfe L (1971) Lymphocyte transformation in patients with Kaposi′s sarcoma. Int J Cancer 8: 468 – 474
Tulpule A, Snyder JC, Espina BM, Higashi L, Satomi M, Lombardy EE, Gill PS (1994) A phase I study of tecogalan, a novel angiogenesis inhibitor in the treatment of AIDS-related Kaposi′s sarcoma and solid tumor. Blood 84: 248a
Turpin JA, Metzer M (1991) Retinoids stimulates HIV-1 expression in Monocytes. VII. Int Conf on AIDS, Florence, 16.-21. June, M.A., p 1059
Vogel T, Guo N, Krutzsch HC et al. (1993) Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 53: 74
Volberding PA, Abrams DI, Conant M., Kaslow M, Vranizan K, Ziegler J (1985) Vinblastine therapy for Kaposi′s sarcoma in the acquired immunodeficiency Syndrome. Ann Intern Med 103: 335 – 338
Volberding PA, Mitsuyasu RT, Golando JP, Spiegel RJ (1987) Treatment of Kaposi′s sarcoma with interferon alfa-2b (Intron® A). Cancer 59: 620 – 625
Volm MD, Roenn JH (1995) Treatment strategies for epidemic Kaposi′s sarcoma. Curr Opin Oncol 7: 429 – 436
Werner S, Hofschneider PH, Roth WK (1989) Cells derived from sporadic and AIDS-related Kaposi′s sarcoma reveal identical cytochemical and molecular properties in vitro. Int J Cancer 43: 1137 – 1144
Zabrenetzky V, Harris CC, Steeg PS et al. (1994) Expression of the extracellular matrix molecule thrombospondin inversely correlates with malignant progression in melanoma, lung, and breast carcinoma cell lines. Int J Cancer 59: 191
Zur Hausen H (1991) Viruses in human cancers. Science 254: 1167 – 1173
Zur Hausen H (1996) Viruses in human tumors — reminiscences and perspectives. Cancer Res 68: 4 – 16
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1997 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Brockmeyer, N.H., Mertins, L. (1997). Therapie des HIV-assoziierten Kaposi-Sarkoms. In: Brockmeyer, N.H., Mertins, L. (eds) HIV-Infekt. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-60722-6_12
Download citation
DOI: https://doi.org/10.1007/978-3-642-60722-6_12
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-64525-9
Online ISBN: 978-3-642-60722-6
eBook Packages: Springer Book Archive